Combination treatment for acute ischemic stroke: A ray of Hope?

Journal of Stroke and Cerebrovascular Diseases

Volumn 8, Issue 6, 1999, Pages 359-367

  Fagan, Susan C ^a,b,c   Bowes, Mark P ^a,b,c   Berri, Samir A ^a,b,c   Zivin, Justin A ^a,b,c  

^a WAYNE STATE UNIVERSITY   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cerebral ischemia; Combination; Drug therapy

Indexed keywords

EID: 0005711784     PISSN: 10523057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1052-3057(99)80043-3     Document Type: Review

References (61)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 (1995) 1581-1587
2. Scheinberg P. The biologic basis for the treatment of acute stroke. Neurology 41 (1991) 1867-1873
3. The multicenter Acute Stroke Trial-Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 335 (1996) 145-150
4. Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomized controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 346 (1995) 1509-1514
5. Brott T.G., Haley E.C., Levy D.E., et al. Urgent therapy for stroke. Part 1. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 23 (1992) 632-640
6. Haley E.C., Levy D.E., Brott T.G., et al. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 23 (1992) 641-645
7. von Kummer R., and Hacke W. Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke. Stroke 23 (1992) 646-652
8. del Zoppo G.J., Poeck K., Pessin M.S., et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 32 (1992) 78-86
9. Hacke W., Kaste M., Fieschi C., et al., ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 274 (1995) 1017-1025
10. Donnan G.A., Davis S.M., Chambers B.R., et al., Australian Streptokinase (ASK) Trial Study Group. Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA 276 (1996) 961-966
11. Lyden P.D., Madden K.P., Clark W.M., et al. Incidence of cerebral hemorrhage after treatment with tissue plasminogen activator or streptokinase following embolic stroke in rabbits. Stroke 21 (1990) 1589-1593
12. Adams H.P., Brott T.G., Furlan A.J., et al. Guidelines for thrombolytic therapy for acute stroke: A supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 27 (1996) 1711-1718
13. Beal M.F., Swartz K.J., Finn S.F., et al. Neurochemical characterization of excitotoxin lesions in the cerebral cortex. J neurosci 11 (1991) 147-158
14. Prehn J.H., Backhauss C., and Krieglstein J. Transforming growth factor-beta 1 prevents glutamate neurotoxicity in rat neocortical cultures and protects mouse neocortex from ischemic injury in vivo. J Cereb Blood Flow Metab 13 (1993) 521-525
15. Cotman C.W., and Iversen L.L. Excitatory amino acids in the brain-focus on NMDA receptors. Trends Neurosci 10 (1987) 263-265
16. Choi D.W. Methods for antagonizing glutamate neurotoxicity. Cerebrovasc Brain Metab Rev 2 (1990) 105-111
17. Mitani A., Yanase H., Sakai K., et al. Origin of intracellular Ca2+ elevation induced by in vitro ischemia-like condition in hippocampal slices. Brain Res 601 (1993) 103-110
18. Seisjo B.K. Basic mechanisms of traumatic brain damage. Ann Emerg Med 22 (1993) 959-969
19. Tymianski M., Wallace M.C., Spigelman I., et al. Cell-permanent Ca2+ chelators reduce early excitotoxic and ischemic neuronal injury in vitro and in vivo. neuron 11 (1993) 221-235
20. Ames A.I., Wright L.W., Kowada M.P., et al. Cerebral ischemia. II. The no-reflow phenomenon. Am J Pathol 52 (1968) 437-447
21. Hallenbeck J.M., and Dutka A.J. Background review and current concepts of reperfusion injury. Arch Neurol 47 (1990) 1245-1254
22. Harlan J.M., Vedder N.B., Winn R.K., et al. Mechanisms and consequences of leukocyte-endothelial interaction. West J Med 155 (1991) 365-369
23. Braide M., Amundson B., Chien S., et al. Quantitative studies on the influence of leukocytes on the vascular resistance in a skeletal muscle preparation. Microvasc Res 27 (1984) 331-352
24. Engler R.L., Dahlgren M., Morris D., et al. Role of leukocytes in response to acute myocardial ischemia and reflow in dogs. Am J Physiol 251 (1986) 314-323
25. Schmid-Schnbein G.W. Capillary plugging by granulocytes and the no-reflow phenomenon in the microcirculation. Proc Fed Amer Soc Exp Biol 46 (1987) 2397-2401
26. Mullane K.M., Westlin W., and Kraemer R. Activated neutrophils release mediators that may contribute to myocardial dysfunction associated with ischemia and reperfusion. Ann NY Acad Sci 524 (1988) 103-121
27. Weiss S.J. Tissue destruction by neutrophils. N Engl J Med 320 (1989) 365-375
28. Bowes M.P., Rothlein R., Fagan S.C., et al. Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy. Neurology 45 (1995) 815-819
29. Clark W.M., Madden K.P., Rothlein R., et al. Reduction of central nervous system ischemic injury in rabbits using leukocyte adhesion antibody treatment. Stroke 22 (1991) 877-883
30. Simpson P.J., Todd III R.F., Fantone J.C., et al. Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mol, anti CD11b) that inhibits leukocyte adhesion. J Clin Invest 81 (1988) 624-629
31. Zivin J.A., Fisher M., DeGirolami U., et al. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 230 (1985) 1289-1292
32. Zivin J.A., and Mazzarella V. Tissue plasminogen activator plus glutamate antagonist improves outcome after embolic stroke. Arch Neurol 48 (1991) 1235-1238
33. Madden K.P., Clark W.M., Kochhar A., et al. Efficacy of LY233053, a competitive glutamate antagonist, in experimental central nervous system ischemia. J Neurosurg 76 (1992) 106-110
34. Kochhar A., Zivin J.A., and Mazzarella V. Pharmacologic studies of the neuroprotective actions of a glutamate antagonist in ischemia. J Neurotrauma 8 (1991) 175-186
35. Buchan A., and Pulsinelli W.A. Hypothermia but not the N-methyl-D-aspartate antagonist, MK-801, attenuates neuronal damage in gerbils subjected to transient global ischemia. J Neurosci 10 (1990) 311-316
36. Sereghy T., Overgaard K., and Boysen G. Neuroprotection by excitatory amino acid antagonist augments the benefit of thrombolysis in embolic stroke in rats. Stroke 24 (1993) 1702-1708
37. Lekieffre D., Benavides J., Scatton B., et al. Neuroprotection afforded by a combination of eliprodil and a thrombolytic agent, rt-PA, in a rat thromboembolic stroke model. Brain Res 776 (1997) 88-95
38. Meden P., Overgaard K., Sereghy T., et al. Enhancing the efficacy of thrombolysis by AMPA receptor blockade with NBQX in a rat embolic stroke model. J Neurol Sci 119 (1993) 209-216
39. Overgaard K., Sereghy T., Pedersen H., et al. neuroprotection with NBQX and thrombolysis with rt-PA in rat embolic stroke. Neurol Res 15 (1993) 344-349
40. Bleich S.D., Nichols T.C., Schumacher R.R., et al. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 66 (1990) 1412-1417
41. Clark W.M., Madden K.P., Lyden P.D., et al. Cerebral hemorrhagic risk of aspirin or heparin therapy with thrombolytic treatment in rabbits. Stroke 22 (1991) 872-876
42. Carter L.P., Guthkelch A.N., Orozco J., et al. Influence of tissue plasminogen activator and heparin on cerebral ischemia in a rabbit model. Stroke 23 (1992) 883-888
43. Umemura K., Wada K., Uematsu T., et al. Evaluation of the combination of a tissue-type plasminogen activator, SUN9216, and a thromboxane A2 receptor antagonist, vapiprost, in a rat middle cerebral artery thrombosis model. Stroke 24 (1993) 1077-1082
44. Bowes M.P., Zivin J.A., and Rothlein R. Monoclonal antibody to the ICAM-1 adhesion site reduces neurological damage in a rabbit cerebral embolism stroke model. Exp Neurol 119 (1992) 215-219
45. Choi D.W. Calcium-mediated neurotoxicity: Relationship to specific channel types and role in ischemic damage. Trends Neurosic 11 (1988) 465-469
46. MacDermott A.B., Mayer M.L., Westbrook G.L., et al. NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurones. Nature 321 (1986) 519-522
47. Uematsu D., Araki N., Greenberg J.H., et al. Combined therapy with MK-801 and nimodipine for protection of ischemic brain damage. Neurology 41 (1991) 88-94
48. Rod M.R., and Auer R.N. Combination therapy with nimodipine and dizocilpine in a rat model of transient forebrain ischemia. Stroke 23 (1992) 725-732
49. Hewitt K., and Corbett D. Combined treatment with MK-801 and nicardipine reduces global ischemic damage in the gerbil. Stroke 23 (1992) 82-86
50. Buchan A.M., Lesiuk H., Barnes K.A., et al. AMPA antagonists: Do they hold more promise for clinical stroke trials then NMDA antagonists?. Stroke 24 (1993) I
51. Gill R., and Woodruff G.N. The neuroprotective actions of kynurenic acid and MK-801 in gerbils are synergistic and not related to hypothermia. Eur J Pharmacol 176 (1990) 143-149
52. Lyden P., and Lonzo L. Combination therapy protects ischemic brain in rats. Glutamate antagonist plus a gamma-Aminobutyric Acid antagonist. Stroke 25 (1994) 189-196
53. Lyden P., Lonzo L., and Nunez S. Combination chemotherapy extends the therapeutic window to 60 minutes after stroke. J Neurotrauma 12 (1995) 223-230
54. Andrews R.J., and Muto R.P. Retraction brain ischemia: Mannitol plus nimodipine preserves both cerebral blood flow and evoked potentials during normoventilation and hyperventilation. Neurol Res 14 (1992) 19-25
55. Katayama Y., Kashiwagi F., Memezawa H., et al. Effect of a prostacyclin derivative (OP-41483) and a hyperosmotic agent (glycerol) on brain edema and metabolism in cerebral ischemia. Jpn Circ J 56 (1992) 1239-1247
56. Kochanek P.M., Dutka A.J., and Hallenbeck J.M. Indomethacin, prostacyclin, and heparin improve postischemic cerebral blood flow without affecting early postischemic granulocyte accumulation. Stroke 18 (1987) 634-637
57. Aronowski J., Strong R., and Grotta J.C. Combined neuroprotection and reperfusion therapy for stroke. Stroke 27 (1996) 1571-1576
58. Pettigrew L.C., Hazle J.D., Gutierrez G., et al. Correction of ischemic brain acidosis with SQ29,548/1-benzylimidazole. Neurol Res 14 (1992) 335-339
59. Shuaib A., Ijaz S., Mazagri R., et al. CGS-19755 is neuroprotective during repetitive ischemia: This effect is significantly enhanced when combined with hypothermia. Neuroscience 56 (1993) 915-920
60. Shuaib A., Waqar T., Wishart T., et al. Post-ischemic therapy with CGS-19755 (alone or in combination with hypothermia) in gerbils. Neurosci Lett 191 (1995) 87-90
61. Sacchette M.L., Toni D., Fiorelli M., et al. The concept of combination therapy in acute ischemic stroke. Neurology 49 (1997) S70-S74